Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 55Neoplasm Metastasis 17Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasms 14Pancreatic Neoplasms 11Uveal Melanoma 10Prostatic Neoplasms 10Leukemia, Myeloid, Acute 9Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Myelodysplastic Syndromes 7Lymphoma 7Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Recurrence 5Myeloproliferative Disorders 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Glioblastoma 5Urinary Bladder Neoplasms 4Ovarian Neoplasms 4

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3aflibercept 2Trastuzumab 2Specimen Handling 2Cisplatin 2Carboplatin 2vinflunine 1tipifarnib 1erdafitinib 1enzalutamide 1entinostat 1enfortumab vedotin 1cabozantinib 1avelumab 1Thalidomide 1Sorafenib 1Ramucirumab 1Radiotherapy 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Ipilimumab 1Introns 1Interleukin-12 Subunit p35 1Interleukin-12 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urethral Neoplasms × Ipilimumab × Clear all
NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡